Our findings suggest that PBA medication may be a promising candidate for the development of therapeutic intervention for preventing or delaying vision loss and retinal degeneration in patients with the RP-associated IRBP mutation. This evidence concerns the gene RBP3 and retinitis pigmentosa 1.